Asciminib provided superior and durable improvements in terms of MMR and BCR::ABL1IS ≤ 1% in Japanese patients with CML-CP previously treated with ≥ 2 TKIs. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.